EN
We strive to make patients-driven cellular immunotherapy innovation,
to transform cancer into a manageable condition — and ultimately cure it.
 
HomeNews and MediaIndustry Trends
Expert opinions:Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D ligand system
  • 0










 


  • Pre:--
  • Next:--

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer